Diagnóstico de neumonía COVID-19 en pacientes asintomáticos tras la realización de un PET/TC oncológico

Mucientes, Jorge; Pernett, R. Jimeno; Arboniés, J. Cardona

doi:10.1016/j.remn.2020.04.004

Cited by 7 publications

(16 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From the comprehensive computer literature search of PubMed/MEDLINE and Cochrane databases, 169 records were screened. In total, 11 studies were selected and retrieved in full-text version according to the predefined inclusion criteria [ 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 ]. Conversely, 158 records were excluded because case reports or small case series ( n = 51), reviews, editorials, letters ( n = 39) or because they were outside the field of interest of this review ( n = 68).…”

Section: Resultsmentioning

confidence: 99%

“…In most of the studies, 2-[ 18 F]FDG PET/CT was performed in patients evaluated for standard indications (mostly oncological indications) and incidental findings suspicious of SARS-CoV-2 infection or COVID-19 at whole-body 2-[ 18 F]FDG PET/CT were described [ 7 , 8 , 9 , 10 , 12 , 13 , 14 , 15 , 16 , 17 ]. Only in one study 2-[ 18 F]FDG PET/CT was performed in COVID-19 patients to assess the inflammatory status at the presumed peak of the inflammatory phase [ 11 ].…”

Section: Resultsmentioning

confidence: 99%

“…Most of the included studies reported the rate of incidental findings suspicious of SARS-CoV-2 infection or COVID-19 at 2-[ 18 F]FDG PET/CT performed for standard indications. This rate largely varied among the included studies from 2.1% to 16.2% of all whole body 2-[ 18 F]FDG PET/CT scans [ 7 , 8 , 9 , 12 , 13 , 14 , 15 , 16 , 17 ], based on the prevalence of SARS-CoV-2 infection or COVID-19 during the examination period in a specific country or region [ 11 , 12 , 16 ]. A significant association of the appearance of imaging findings suspicious for COVID-19 on 2-[ 18 F]FDG PET/CT with gender, sex, age, or ethnicity was not demonstrated [ 12 ].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Role of 2-[18F]FDG as a Radiopharmaceutical for PET/CT in Patients with COVID-19: A Systematic Review

Annunziata¹,

Delgado-Bolton

Kamani

et al. 2020

Pharmaceuticals

View full text Add to dashboard Cite

Some recent studies evaluated the role of fluorine-18 fluorodeoxyglucose (2-[18F]FDG) as a radiopharmaceutical for positron emission tomography/computed tomography (PET/CT) imaging in patients with Coronavirus Disease (COVID-19). This article aims to perform a systematic review in this setting. A comprehensive computer literature search in PubMed/MEDLINE and Cochrane library databases regarding the role of 2-[18F]FDG PET/CT in patients with COVID-19 was carried out. This combination of key words was used: (A) “PET” OR “positron emission tomography” AND (B) “COVID” OR “SARS”. Only pertinent original articles were selected; case reports and very small case series were excluded. We have selected 11 original studies of 2-[18F]FDG PET/CT in patients with COVID-19. Evidence-based data showed first preliminary applications of this diagnostic tool in this clinical setting, with particular regard to the incidental detection of interstitial pneumonia suspected for COVID-19. To date, according to evidence-based data, 2-[18F]FDG PET/CT cannot substitute or integrate high-resolution CT to diagnose suspicious COVID-19 or for disease monitoring, but it can only be useful to incidentally detect suspicious COVID-19 lesions in patients performing this imaging method for standard oncological and non-oncological indications. Published data about the possible role of 2-[18F]FDG PET/CT in patients with COVID-19 are increasing, but larger studies are warranted.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Role of 2-[18F]FDG as a Radiopharmaceutical for PET/CT in Patients with COVID-19: A Systematic Review

Annunziata¹,

Delgado-Bolton

Kamani

et al. 2020

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…The positive confirmatory test observed in 14/23 patients represent a true prevalence of COVID-19 pneumonia of 1.3% in our sample. The prevalence reported by small case series are broadly variable (from 8 to 38%), since they are related with cancer subjects with suspicious CT findings and partial or total absence of laboratory confirmation [22][23][24]. Our very low prevalence could be related with more restrictive criteria applied to select the cancer patients derived to 18 F-FDG PET-CT and the heterogeneous, unpredictable prevalence of the disease during different study periods.…”

Section: Frequency Of Covid-19 Pneumonia In Asymptomatic Cancer Patientsmentioning

confidence: 77%

“…Five of this 6 patients exhibited small lymph nodes (< 1 cm). The results obtained by previous case series applying 18 F-FDG PET-CT were heterogeneous; Albano et al found mediastinal adenopathies in 1/5 confirmed patients [23], and Rasilla et al did not report lymphoid FDG uptake [24].…”

Section: Ct Findings and Fdg Uptake In The Thoraxmentioning

confidence: 91%

Assessment of extra-parenchymal lung involvement in asymptomatic cancer patients with COVID-19 pneumonia detected on 18F-FDG PET-CT studies

Wakfie-Corieh

García

Ferrando-Castagnetto

et al. 2020

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Background Lung involvement in patients with coronavirus disease 2019 (COVID-19) undergoing PET-CT has been previously reported. However, FDG uptake outside lung parenchyma was poorly characterized in detail. We evaluated the extraparenchymal lung involvement in asymptomatic cancer patients with COVID-19 pneumonia through 18 F-FDG PET-CT. Methods A total of 1079 oncologic 18 F-FDG PET-CT were performed between February 2 and May 18, 2020. Confirmed COVID-19 pneumonia was defined as characteristic ground-glass bilateral CT infiltrates and positive genetic/serologic tests. Nonmetastatic extra-parenchymal lung PET-CT findings were evaluated through qualitative (visual), quantitative (measurements on CT), and semiquantitative (maximum standardized uptake value: SUVmax on PET) interpretation. Clinical data, blood tests, and PET-CT results were compared between patients with and without COVID-19 pneumonia. Results A total of 23 18 F-FDG PET-CT scans with pulmonary infiltrates suggestive of COVID-19 and available laboratory data were included: 14 positive (cases) and 9 negative (controls) for COVID-19 infection, representing a low prevalence of COVID-19 pneumonia (1.3%). Serum lactate dehydrogenase and D-dimers tended to be increased in COVID-19 cases. Extraparenchymal lung findings were found in 42.9% of patients with COVID-19, most frequently as mediastinal and hilar nodes with 18 F-FDG uptake (35.7%), followed by incidental pulmonary embolism in two patients (14.3%). In the control group, extrapulmonary findings were observed in a single patient (11.1%) with 18 F-FDG uptake located to mediastinal, hilar, and cervical nodes. Nasopharyngeal and hepatic SUVmax were similar in both groups. Conclusion In cancer patients with asymptomatic COVID-19 pneumonia, 18 F-FDG PET-CT findings are more frequently limited to thoracic structures, suggesting that an early and silent distant involvement is very rare. Pulmonary embolism is a frequent and potentially severe finding raising special concern. PET-CT can provide new pathogenic insights about this novel disease.

show abstract

COVID-19 in the act: incidental 18F-FDG PET/CT findings in asymptomatic patients and those with symptoms not primarily correlated with COVID-19 during the United Kingdom coronavirus lockdown

Halsey

Priftakis

Mackenzie

et al. 2020

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose The emergence of the novel SARS-CoV-2 pathogen and lethal COVID-19 disease pandemic poses major diagnostic challenges. The study aims to describe the spectrum and prevalence of thoracic and extrathoracic incidental findings in patients who have undergone 18F-FDG PET/CT during the first 3 weeks of the COVID-19 UK lockdown. Methods This is a single-centre retrospective controlled observational study. 18F-FDG PET/CT scans (n = 160) acquired from 23/3/2020 to 9/4/2020 were retrospectively reviewed for incidental findings in the lungs and extrapulmonary sites (heart, nasal sinuses, parotid and salivary glands, colon, large vessels, renal cortex, brain, spleen and testes). A date-matched control group (n = 205) of patients from 2019 was used for comparison. Results The total prevalence of suspicious findings was 26/160 (16.25%). Fifteen patients presented with incidental findings in the lungs, while eleven patients had only non-pulmonary incidental findings. There was a significant increase in the appearance of incidental 18F-FDG PET/CT findings during the 2nd week (OR = 3.8) and 3rd week (OR = 7.6) in relation to the 1st week. There was a significant increase in the average maximum standardised uptake values (SUVmax) in the parotid/salivary glands of patients scanned during week 2 in relation to week 1 (p = 0.036). There was no significant difference in the prevalence of

show abstract

Diagnóstico de neumonía COVID-19 en pacientes asintomáticos tras la realización de un PET/TC oncológico

Cited by 7 publications

References 10 publications

Role of 2-[18F]FDG as a Radiopharmaceutical for PET/CT in Patients with COVID-19: A Systematic Review

Role of 2-[18F]FDG as a Radiopharmaceutical for PET/CT in Patients with COVID-19: A Systematic Review

Assessment of extra-parenchymal lung involvement in asymptomatic cancer patients with COVID-19 pneumonia detected on 18F-FDG PET-CT studies

COVID-19 in the act: incidental 18F-FDG PET/CT findings in asymptomatic patients and those with symptoms not primarily correlated with COVID-19 during the United Kingdom coronavirus lockdown

Contact Info

Product

Resources

About